| CASE REPORT |
|
| Year : 2016 | Volume
: 9
| Issue : 3 | Page : 164-166 |
|
|
Minimal exposure intra-arterial chemotherapy for children with retinoblastoma and 13q syndrome
Alexander B Dillon1, Alexzandra Douglass2, Pascal Jabbour3, Carol L Shields2
1 School of Medicine, New York University, New York, USA
2 Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, USA
3 Department of Neurosurgery, Thomas Jefferson University, Philadelphia, USA
Correspondence Address:
Carol L Shields
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, 840 Walnut Street, Suite 1440, Philadelphia, PA 19107
USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0974-620X.192278
|
|
|
Two infants with retinoblastoma and 13q syndrome with multiorgan system anomalies were treated with targeted intra-arterial chemotherapy (IAC) using one-to-three cycles of melphalan 5 mg to avoid systemic chemotherapeutic side effects. Both patients showed good response, with tumor control and no systemic chemotherapy side effects. Of the treatment modalities currently available, IAC may represent an optimal balance between tumor extermination and adverse drug reactions in this patient population with classically reduced multiorgan reserve. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
